Advertisement Dutch bioscience firm Pantarhei looks to buy Merck Netherlands unit - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Dutch bioscience firm Pantarhei looks to buy Merck Netherlands unit

Pantarhei, a Denmark-based bioscience company, is planning to bid for the bulk of Merck's Netherlands-based bioscience research unit Organan, which Merck acquired in its merger with Schering-Plough.

Reportedly, Pantarhei now has secured backing from international private equity investors.

Reuters quoted Pantarhei Bioscience director (and former Organon executive) Herjan Coeling Bennink as telling the Dutch Financieele Dagblad that the company is thinking of making the proposal thanks to the backing from international private equity investors.

Merck had postponed the closure of Organon’s R&D activities in Holland while it negotiated on potential alternatives including a sale, the initial deadline of which was 31 December 2010 which was later pushed back to 15 February.